CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- Open-market buys, last 90 days
- $38,094
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$38,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-06-15 | BATE KENNETH Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-03-01 | Reverberi Gian Piero SVP & Chief Commercial Officer | Grant or award | +30,000 | 50,000 | ||
| 2017-03-01 | Reverberi Gian Piero SVP & Chief Commercial Officer | Grant or award · Employee Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2017-03-01 | Polymeropoulos Mihael Hristos President and CEO | Grant or award | +200,000 | 1,041,848 | ||
| 2017-03-01 | Polymeropoulos Mihael Hristos President and CEO | Grant or award · Employee Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2017-03-01 | Kelly James Patrick EVP & Chief Financial Officer | Grant or award | +70,000 | 139,721 | ||
| 2017-03-01 | Kelly James Patrick EVP & Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2017-03-01 | Gulino Richard L. SVP, General Counsel & Sec. | Grant or award | +30,000 | 39,100 | ||
| 2017-03-01 | Gulino Richard L. SVP, General Counsel & Sec. | Grant or award · Employee Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2017-01-03 | Baroldi Paolo SVP & Chief Medical Officer | Exercise or conversion | +12,500 | 53,165 | ||
| 2017-01-03 | Baroldi Paolo SVP & Chief Medical Officer | Exercise or conversion | +5,000 | 58,165 | ||
| 2017-01-03 | Baroldi Paolo SVP & Chief Medical Officer | Exercise or conversion | +5,000 | 63,165 | ||
| 2017-01-03 | Baroldi Paolo SVP & Chief Medical Officer | Exercise or conversion | +7,500 | 70,665 | ||
| 2017-01-03 | Baroldi Paolo SVP & Chief Medical Officer | Sale | +16,300 | $15.51 | $253K | 54,365 |
| 2017-01-03 | Baroldi Paolo SVP & Chief Medical Officer | Exercise or conversion · Restricted Stock Unit | +12,500 | 0 | ||
| 2017-01-03 | Baroldi Paolo SVP & Chief Medical Officer | Exercise or conversion · Restricted Stock Unit | +5,000 | 5,000 | ||
| 2017-01-03 | Baroldi Paolo SVP & Chief Medical Officer | Exercise or conversion · Restricted Stock Unit | +5,000 | 10,000 | ||
| 2017-01-03 | Baroldi Paolo SVP & Chief Medical Officer | Exercise or conversion · Restricted Stock Unit | +7,500 | 22,500 | ||
| 2017-01-03 | Gulino Richard L. SVP, General Counsel & Sec. | Exercise or conversion | +12,500 | 12,500 | ||
| 2017-01-03 | Gulino Richard L. SVP, General Counsel & Sec. | Exercise or conversion | +7,500 | 20,000 |
Page 22 of 36 · 717 trades